Practice Essentials in Pancreatic Cancer

 Drug Sequencing Strategies in Metastatic Pancreatic Cancer
Drug Sequencing Strategies in Metastatic Pancreatic Cancer
CME, CPE
Bert H. O’Neil, MD
Release Date: April 17, 2017
Expiration Date: April 17, 2018

In this activity, participants will be provided with an overview of treatment paradigms for first- and second-line metastatic pancreatic cancer, and insight into different drug sequencing strategies tailored to individual patient- and disease-related factors, such as age, comorbidities, performance status, and response/toxicity to prior therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation
Begin, Earn CreditView Only, No Credit
 
Establishing a Palliative Care Plan for Patients with Pancreatic Cancer
Establishing a Palliative Care Plan for Patients with Pancreatic Cancer
CME, CPE
David Hui, MD
Release Date: October 26, 2016
Expiration Date: October 26, 2017

Studies indicate that when patients with pancreatic cancer are treated with therapeutic strategies that include effective palliative care, outcomes are improved. This activity will address the goals and rationale of palliative care in pancreatic cancer, and provide practical guidance for developing effective palliative care strategies for every pancreatic cancer patient.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
Begin, Earn CreditView Only, No Credit
 
The Future of Personalized Medicine in Pancreatic Cancer
The Future of Personalized Medicine in Pancreatic Cancer
CME, CPE
Eileen M. O'Reilly, MD
Release Date: April 25, 2016
Expiration Date: April 25, 2017
Over the past several years, a number of biomarkers have been investigated in pancreatic adenocarcinoma, but to date, none have been validated for routine clinical decision-making. In this activity, Dr. Eileen O’Reilly presents a state-of-the-state synopsis of our current understanding of potential diagnostic biomarkers, briefly reviewing those that have been investigated and failed to achieve success, as well as those that are showing promise for use in the clinical setting in the near future.

To download the accompanying e-Transcript for reference purposes only click here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 
Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy
Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy
CME, CPE
Philip A. Philip, MD, PhD, FRCP
Release Date: February 19, 2016
Expiration Date: February 19, 2017
This activity will address therapies beyond gemcitabine monotherapy for pancreatic cancer, including other recommended options for first-line treatment such as FOLFIRINOX and gemcitabine combinations with nab-paclitaxel, erlotinib, and other agents.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation
View Only, CE ExpiredView Only, No Credit
 

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved